Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes

EM. Hylek, C. Held, JH. Alexander, RD. Lopes, R. De Caterina, DM. Wojdyla, K. Huber, P. Jansky, PG. Steg, M. Hanna, L. Thomas, L. Wallentin, CB. Granger,

. 2014 ; 63 (20) : 2141-7.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14074251

OBJECTIVES: This study sought to characterize major bleeding on the basis of the components of the major bleeding definition, to explore major bleeding by location, to define 30-day mortality after a major bleeding event, and to identify factors associated with major bleeding. BACKGROUND: Apixaban was shown to reduce the risk of major hemorrhage among patients with atrial fibrillation in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. METHODS: All patients who received at least 1 dose of a study drug were included. Major bleeding was defined according to the criteria of the International Society on Thrombosis and Haemostasis. Factors associated with major hemorrhage were identified using a multivariable Cox model. RESULTS: The on-treatment safety population included 18,140 patients. The rate of major hemorrhage among patients in the apixaban group was 2.13% per year compared with 3.09% per year in the warfarin group (hazard ratio [HR] 0.69, 95% confidence interval [CI]: 0.60 to 0.80; p < 0.001). Compared with warfarin, major extracranial hemorrhage associated with apixaban led to reduced hospitalization, medical or surgical intervention, transfusion, or change in antithrombotic therapy. Major hemorrhage followed by mortality within 30 days occurred half as often in apixaban-treated patients than in those receiving warfarin (HR 0.50, 95% CI: 0.33 to 0.74; p < 0.001). Older age, prior hemorrhage, prior stroke or transient ischemic attack, diabetes, lower creatinine clearance, decreased hematocrit, aspirin therapy, and nonsteroidal anti-inflammatory drugs were independently associated with an increased risk. CONCLUSIONS: Apixaban, compared with warfarin, was associated with fewer intracranial hemorrhages, less adverse consequences following extracranial hemorrhage, and a 50% reduction in fatal consequences at 30 days in cases of major hemorrhage.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14074251
003      
CZ-PrNML
005      
20141009094439.0
007      
ta
008      
141006s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jacc.2014.02.549 $2 doi
035    __
$a (PubMed)24657685
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hylek, Elaine M $u Boston University Medical Center, Boston, Massachusetts. Electronic address: ehylek@bu.edu.
245    10
$a Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes / $c EM. Hylek, C. Held, JH. Alexander, RD. Lopes, R. De Caterina, DM. Wojdyla, K. Huber, P. Jansky, PG. Steg, M. Hanna, L. Thomas, L. Wallentin, CB. Granger,
520    9_
$a OBJECTIVES: This study sought to characterize major bleeding on the basis of the components of the major bleeding definition, to explore major bleeding by location, to define 30-day mortality after a major bleeding event, and to identify factors associated with major bleeding. BACKGROUND: Apixaban was shown to reduce the risk of major hemorrhage among patients with atrial fibrillation in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. METHODS: All patients who received at least 1 dose of a study drug were included. Major bleeding was defined according to the criteria of the International Society on Thrombosis and Haemostasis. Factors associated with major hemorrhage were identified using a multivariable Cox model. RESULTS: The on-treatment safety population included 18,140 patients. The rate of major hemorrhage among patients in the apixaban group was 2.13% per year compared with 3.09% per year in the warfarin group (hazard ratio [HR] 0.69, 95% confidence interval [CI]: 0.60 to 0.80; p < 0.001). Compared with warfarin, major extracranial hemorrhage associated with apixaban led to reduced hospitalization, medical or surgical intervention, transfusion, or change in antithrombotic therapy. Major hemorrhage followed by mortality within 30 days occurred half as often in apixaban-treated patients than in those receiving warfarin (HR 0.50, 95% CI: 0.33 to 0.74; p < 0.001). Older age, prior hemorrhage, prior stroke or transient ischemic attack, diabetes, lower creatinine clearance, decreased hematocrit, aspirin therapy, and nonsteroidal anti-inflammatory drugs were independently associated with an increased risk. CONCLUSIONS: Apixaban, compared with warfarin, was associated with fewer intracranial hemorrhages, less adverse consequences following extracranial hemorrhage, and a 50% reduction in fatal consequences at 30 days in cases of major hemorrhage.
650    _2
$a senioři $7 D000368
650    _2
$a antikoagulancia $x aplikace a dávkování $x škodlivé účinky $7 D000925
650    _2
$a fibrilace síní $x komplikace $x farmakoterapie $7 D001281
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a krvácení $x chemicky indukované $x epidemiologie $7 D006470
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a pyrazoly $x aplikace a dávkování $x škodlivé účinky $7 D011720
650    _2
$a pyridony $x aplikace a dávkování $x škodlivé účinky $7 D011728
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a cévní mozková příhoda $x epidemiologie $x etiologie $x prevence a kontrola $7 D020521
650    _2
$a míra přežití $x trendy $7 D015996
650    _2
$a tromboembolie $x komplikace $x prevence a kontrola $7 D013923
650    _2
$a warfarin $x aplikace a dávkování $x škodlivé účinky $7 D014859
650    _2
$a celosvětové zdraví $7 D014943
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Held, Claes $u Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
700    1_
$a Alexander, John H $u Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina. $7 gn_A_00003908
700    1_
$a Lopes, Renato D $u Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
700    1_
$a De Caterina, Raffaele $u G. d'Annunzio University, Chieti, Italy.
700    1_
$a Wojdyla, Daniel M $u Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
700    1_
$a Huber, Kurt $u Wilhelminen Hospital, Vienna, Austria.
700    1_
$a Jansky, Petr $u Motol University Hospital, Prague, Czech Republic.
700    1_
$a Steg, Philippe Gabriel $u Hôpital Bichat-Claude Bernard, Paris, France.
700    1_
$a Hanna, Michael $u Bristol-Myers Squibb, Princeton, New Jersey.
700    1_
$a Thomas, Laine $u Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
700    1_
$a Wallentin, Lars $u Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
700    1_
$a Granger, Christopher B $u Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
773    0_
$w MED00002964 $t Journal of the American College of Cardiology $x 1558-3597 $g Roč. 63, č. 20 (2014), s. 2141-7
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24657685 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20141006 $b ABA008
991    __
$a 20141009094828 $b ABA008
999    __
$a ok $b bmc $g 1042134 $s 873163
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 63 $c 20 $d 2141-7 $i 1558-3597 $m Journal of the American College of Cardiology $n J. Am. Coll. Cardiol. $x MED00002964
LZP    __
$a Pubmed-20141006

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace